Background: The impact of age on the efficacy and safety of immunotherapy remains controversial. The previous studies simply classified patients into younger and older groups, which might not reflect the real impact of young age on immunotherapy efficacy. The current study aimed to explore the efficacy and safety of immune checkpoint inhibitor (ICI) combined therapy in young (aged 18-44 years), middle-aged (aged 45-65 years), and old (aged >65 years) patients with metastatic gastrointestinal cancers (GICs), and further determine the role of immunotherapy in young patients.
Methods: Patients with metastatic GIC including esophageal cancer (EC), gastric cancer (GC), hepatocellular cancer (HCC), and biliary tract cancer (BTC) who received ICI combination therapy were enrolled, divided into young (aged 18-44 years), middle-aged (aged 45-65 years), and old (aged >65 years) groups. The clinical characteristics, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAEs) were compared among three groups.
Results: A total of 254 patients were finally included, with 18, 139, and 97 cases in the young (aged 18-44 years), middle-aged (aged 45-65 years), and old (aged >65 years) groups, respectively. Compared to middle-aged and old patients, young patients had lower DCR (all < 0.05) and also had inferior PFS ( < 0.001) and OS ( 0.017). The multivariate analyses showed that young age was an independent prognostic factor for PFS [hazard ratio (HR) 3.474, 95% confidence interval (CI) 1.962-6.150, < 0.001] and OS (HR 2.740, 95% CI 1.348-5.570, = 0.005). Subsequent safety analyses referring to irAEs demonstrated no significant differences for distribution frequency among each age group (all > 0.05), whereas patients with irAEs displayed better DCR ( = 0.035) and PFS ( = 0.037).
Conclusion: Younger GIC patients (aged 18-44 years) showed poor efficacy for ICI combined therapy, and irAEs could be used as a clinical biomarker to predict ICI efficacy in metastatic GIC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189879 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1155019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between asthma and cardiovascular disease: evidence from the national health and nutrition examination survey 1999-2018.
Front Cardiovasc Med
December 2024
Department of Cardiovascular Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, China.
Background: Cardiovascular disease(CVD) remains a significant global challenge. Asthma, which is characterized by airway hyperresponsiveness and reversible and limited airflow, plays an important role in cardiovascular diseases. This study aimed to investigate the association between asthma and CVD.
View Article and Find Full Text PDFIncidence and Risk Factors of Diagnosed Young-Adult-Onset Type 2 Diabetes in the U.S.: The National Health Interview Survey 2016-2022.
Diabetes Care
January 2025
Department of Epidemiology and Biostatistics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- The study aimed to assess the incidence and risk factors of diagnosed type 2 diabetes (T2D) among young adults in the U.S.
- Analysis was conducted on a large sample of adults aged 18-79 using data from the National Health Interview Survey from 2016 to 2022, focusing particularly on the younger age group (18-44 years).
- The research found that young-adult-onset T2D has an incidence of 3.0 per 1000 adults, with higher risk factors linked to minority status, socioeconomic disadvantages, obesity, and certain medication uses, highlighting the need for targeted prevention strategies.
[Prevalence and trends of overweight, obesity, and central obesity among adult residents in 10 provinces (autonomous regions) of China in 2000-2023].
Wei Sheng Yan Jiu
November 2024
NHC Key Laboratory of Public Nutrition and Health, National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Objective: To describe the prevalence of overweight, obesity, and central obesity among adult residents aged 18 years and above in 10 provinces(autonomous regions) of China in 2023, and to analyze the trends in 2000-2023.
Methods: Adults aged 18 and over with complete height, weight and waist circumference measurements who participated in the 2000-2018 China Health and Nutrition Survey and the 2022-2023 China Development and Nutrition Health Impact Cohort Survey from the same 10 provinces(autonomous regions) were selected as the study subjects. Overweight, obesity, pre-central obesity, and central obesity were defined according to the Chinese Adult Weight criteria(WS/T 428-2013).
Metabolic Syndrome and Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy in Northern Tanzania.
J Int Assoc Provid AIDS Care
December 2024
Department of Internal Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Purpose: Chronic systemic inflammation from human immunodeficiency virus (HIV) may cause metabolic abnormalities in lipid metabolism. Additionally, the development of metabolic syndrome has been associated with specific anti-retroviral therapy, particularly dolutegravir. This study aimed to determine the prevalence and associated factors of metabolic syndrome among people living with HIV on dolutegravir-based anti-retroviral therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!